INPP5D Antibody

What is INPP5D and why is it important in neurodegenerative research?

INPP5D (Inositol Polyphosphate-5-Phosphatase D), also known as SHIP1, is a phosphatase enzyme primarily expressed in myeloid cells including microglia. It negatively regulates PI3K signaling by dephosphorylating PIP3 to generate PIP2, thereby inhibiting downstream signaling events . INPP5D has gained significant importance in neurodegenerative research after being genetically associated with Alzheimer's disease (AD) through genome-wide association studies . Recent evidence shows INPP5D regulates inflammasome activation in microglia, suggesting a mechanistic link between INPP5D dysfunction and neuroinflammatory processes in AD .

Which cell types express INPP5D in the human brain?

INPP5D expression in the human brain is largely restricted to microglial cells. Immunostaining of human post-mortem brain tissue shows co-localization of INPP5D with IBA1, a microglial and macrophage-specific calcium-binding protein . Studies using iPSC-derived cell types confirm this specificity - when comparing iPSC-derived microglia (iMGs), astrocytes (iAs), neurons (iNs), and endothelial cells (iECs), INPP5D protein expression was detected exclusively in iMGs .

Note: These ranges are based on commercially available antibodies . Exact dilutions should be optimized for each experimental system and antibody lot.

How can I distinguish between different INPP5D isoforms using antibodies?

INPP5D has multiple isoforms, some of which lack the phosphatase domain and are predicted to be inactive . To distinguish between isoforms:

• Select antibodies targeting specific domains: Use antibodies recognizing epitopes within the phosphatase domain to detect functionally active INPP5D.

• Molecular weight analysis: Full-length INPP5D has a predicted molecular weight of approximately 145 kDa. Truncated variants display distinct migration patterns on western blots .

• Peptide mapping approach: Mass spectrometry analysis can reveal differential peptide coverage across domains. Research shows a reduction in peptides mapping to the phosphatase domain and an elevation in C-terminal peptides in AD brain tissue .

• Antibody validation: Use INPP5D knockout or biallelic loss-of-function models to confirm specificity. Multiple antibodies (e.g., C40G9 and ab45142) may show slightly different banding patterns but should all show loss of signal in knockout samples .

What are the challenges in interpreting INPP5D protein levels in AD brain tissue?

Interpreting INPP5D levels in AD brain presents several challenges:

• Multiple protein pools: Evidence suggests different pools of INPP5D exist in the brain, detectable by different methods. While immunohistochemistry shows increased INPP5D staining in AD brains, western blotting of aqueous-soluble fractions shows reduced full-length INPP5D .

• Altered distribution patterns: In AD brains, INPP5D redistributes from a diffuse to punctate pattern in microglia, particularly in plaque-associated microglia .

• Isoform complexity: Elevation in INPP5D observed by immunostaining may reflect truncated and functionally inactive INPP5D protein generated from isoforms lacking the phosphatase domain .

• Antibody epitope location: Many available antibodies recognize epitopes C-terminal to the phosphatase domain and would detect both active and inactive variants .

• Buffer-dependent extraction: The choice of extraction buffer affects which INPP5D pools are detected. TBS extraction captures aqueous-soluble, cytosolic proteins, while other pools may require different extraction methods .

How can I validate that my INPP5D antibody is detecting the correct protein?

Comprehensive validation strategies include:

• Genetic models: Test antibodies on samples from INPP5D knockout or biallelic loss-of-function models. True INPP5D-specific bands should disappear in these samples .

• Multiple antibodies: Use multiple antibodies targeting different epitopes. Consistent results across antibodies increase confidence in specificity .

• Peptide competition: Pre-incubate antibody with the immunizing peptide before application to samples. This should abolish specific binding .

• Cross-reactivity testing: Test the antibody on samples from different species to confirm expected cross-reactivity patterns .

• Western blot analysis: Confirm detection of the expected molecular weight band (approximately 145 kDa for full-length INPP5D) .

• Positive control tissues: Include known INPP5D-expressing tissues and cell lines such as Daudi cells, Ramos cells, Raji cells, and THP-1 cells .

What methods are recommended for studying INPP5D's role in inflammasome activation?

Based on published methodologies, the following approaches are recommended:

• Pharmacological inhibition: Use 3-alpha-Aminocholestane (3AC) at low concentrations (1.25 μM, below IC₅₀ of 10 μM) to inhibit INPP5D activity acutely .

• Genetic manipulation: Generate CRISPR-Cas9-mediated INPP5D knockout or heterozygous models in iPSC-derived microglia to study chronic reduction of INPP5D .

• Cytokine profiling: Measure secreted IL-1β and IL-18 (inflammasome products) using ELISA or multiplex assays (e.g., MesoScale Discoveries panel) .

• Inflammasome visualization: Detect ASC speck formation (a hallmark of inflammasome assembly) through immunocytochemistry using ASC antibodies .

• Caspase-1 activity: Measure cleaved caspase-1 levels as a direct indicator of inflammasome activation .

• Rescue experiments: Use NLRP3 inhibitors (e.g., MCC950 at 10 μM) or caspase-1 inhibitors to confirm inflammasome involvement .

• Combined RNA/protein analysis: Perform both RNA-seq and proteomic profiling to capture transcriptional and post-translational regulation of inflammasome components .

What are the optimal conditions for INPP5D immunostaining in brain tissue?

For successful INPP5D immunostaining in brain tissue:

How should I design experiments to study phosphorylated INPP5D?

When studying phosphorylated INPP5D:

• Phospho-specific antibodies: Use antibodies specifically targeting phosphorylated residues, such as anti-phospho-SHIP-1 (Y1021) .

• Phosphatase inhibitors: Include phosphatase inhibitors in all buffers during sample preparation to preserve phosphorylation status.

• Positive controls: Include samples from cells treated with agents known to induce INPP5D phosphorylation.

• Validation strategy: Confirm specificity by treating samples with phosphatase before immunoblotting, which should eliminate phospho-specific signal.

• Functional correlations: Correlate phosphorylation status with functional readouts of INPP5D activity, such as PIP3/PIP2 ratios or downstream PI3K signaling events.

How do I reconcile conflicting data regarding INPP5D levels in AD brains?

The apparent contradiction between increased INPP5D staining by immunohistochemistry and decreased water-soluble INPP5D by western blotting in AD brains can be approached as follows:

• Recognize different protein pools: Different detection methods may be capturing different pools of INPP5D protein. Western blotting of TBS-soluble fractions detects primarily cytosolic, water-soluble proteins, while immunostaining may detect both soluble and membrane-associated forms .

• Consider isoform diversity: The elevation in INPP5D observed by immunostaining may reflect truncated variants lacking the phosphatase domain, while full-length, functionally active INPP5D is reduced .

• Examine domain-specific detection: Analysis of peptide-level mass spectrometry data shows reduced peptides mapping to the phosphatase domain and increased peptides from the C-terminus in AD brain, suggesting a shift in isoform expression rather than simple up or down-regulation .

• Functional validation: Focus on functional assays rather than mere protein levels. Loss-of-function models more closely resemble AD microglia transcriptionally, suggesting reduced INPP5D function despite possible increases in certain protein isoforms .

What is the relationship between genetic INPP5D variants and protein function in AD?

The relationship between INPP5D genetic variants and protein function remains complex:

What are emerging techniques for studying INPP5D in neurodegenerative contexts?

Emerging techniques include:

• Single-nucleus RNA sequencing: This approach allows characterization of cell-type specific expression patterns of INPP5D and its correlation with disease states .

• Spatial transcriptomics: These methods can map INPP5D expression patterns in relation to AD pathological features like amyloid plaques.

• CRISPR-based functional genomics: Systematic perturbation of INPP5D and associated pathways using CRISPR screens in relevant cellular models.

• Patient-derived models: iPSC-derived microglia from individuals with different INPP5D risk alleles to study genotype-phenotype correlations.

• In vivo conditional knockouts: Cell-type specific and inducible modulation of INPP5D in animal models of neurodegeneration .

• Therapeutic modulation: Development and testing of compounds that modulate INPP5D activity as potential therapeutic approaches for AD.

How should researchers approach target validation when developing new INPP5D antibodies?

When developing new INPP5D antibodies, comprehensive target validation should include:

• Domain-specific targeting: Design antibodies targeting specific functional domains of INPP5D to distinguish active from inactive isoforms.

• Cross-validation with mass spectrometry: Confirm antibody specificity using independent methods like targeted mass spectrometry.

• Testing across multiple platforms: Validate antibodies across multiple applications (WB, IHC, IP, IF) and sample types.

• Genetic knockout validation: Test new antibodies in CRISPR-engineered INPP5D knockout models to confirm specificity.

• Epitope mapping: Precisely define the binding epitope to understand what regions or isoforms of INPP5D the antibody detects.

• Species cross-reactivity: Characterize cross-reactivity across species to enable translational research between model organisms and human samples.

• Phosphorylation-state specificity: For phospho-specific antibodies, validate specificity using phosphatase treatment and site-directed mutagenesis of the target residue.